Placebo News and Research

RSS

Individuals with less efficient learning mechanisms benefit more from brain stimulation

As we age, our cognitive and motor functions deteriorate, which in turn affects our independence and overall quality of life.

27 Nov 2024

Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity

Genetically attenuated malaria parasites with extended liver-stage arrest (GA2) showed 89% protection in a clinical trial, surpassing earlier vaccine candidates and highlighting the potential of cellular immunity.

26 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024

Hormone therapy in early menopause proves safe but lacks cognitive benefits

Early menopausal hormone therapy neither benefits nor harms long-term cognition, offering reassurance but no protection against cognitive decline in healthy women.

26 Nov 2024

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.

25 Nov 2024

Wearable electrical nerve stimulation device can reduce pain and fatigue linked to long COVID

A wearable electrical nerve stimulation device can provide relief to people experiencing the persistent pain and fatigue linked to long COVID, a study co-led by UCLA and Baylor College of Medicine researchers suggests.

25 Nov 2024

Short-term menopausal hormone therapy shows no long-term cognitive effects

Short-term menopausal hormone therapy (MHT) did not have long-term cognitive effects when given to women in early postmenopause, according to a study published November 21st in the open-access journal PLOS Medicine by Carey Gleason from the University of Wisconsin-Madison, USA, and colleagues.

22 Nov 2024

Fermented kimchi may help combat obesity by regulating gut microbiota

Kimchi consumption significantly reduces body fat and enhances metabolic indicators in overweight individuals, highlighting its role in obesity management.

22 Nov 2024

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.

21 Nov 2024

Oral medication sodium oxybate shows promise for treating laryngeal dystonia

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social life, employment and mental health.

20 Nov 2024

Kimchi found to significantly reduce body fat and combat obesity

Approximately 16% of the global population, or about 890 million people, suffer from obesity. The World Health Organization (WHO) has recognized obesity as a significant health issue and highlighted its impact on the quality of life and overall health of individuals across the world.

20 Nov 2024

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

Low-dose ketamine may be an effective adjunct analgesic to morphine for managing acute pain

A new study that investigates low-dose ketamine (LDK) as an adjunct to morphine for treating acute pain has been published in the October issue of Academic Emergency Medicine (AEM), the peer-reviewed journal of the Society for Academic Emergency Medicine (SAEM).

19 Nov 2024

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, that are being simultaneously presented at the American Heart Association's 2024 Scientific Sessions.

19 Nov 2024

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

19 Nov 2024

Multiple sclerosis drug could help individuals with reduced working memory

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions like schizophrenia or depression.

19 Nov 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Hypertension drug may reduce heart failure risk in people recovering from heart attack

New research found that the medication spironolactone, often prescribed for hypertension (high blood pressure), may reduce the risk of heart failure in people recovering from a heart attack.

18 Nov 2024

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Placebo News and Research

Individuals with less efficient learning mechanisms benefit more from brain stimulation

Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Hormone therapy in early menopause proves safe but lacks cognitive benefits

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Wearable electrical nerve stimulation device can reduce pain and fatigue linked to long COVID

Short-term menopausal hormone therapy shows no long-term cognitive effects

Fermented kimchi may help combat obesity by regulating gut microbiota

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Oral medication sodium oxybate shows promise for treating laryngeal dystonia

Kimchi found to significantly reduce body fat and combat obesity

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

Low-dose ketamine may be an effective adjunct analgesic to morphine for managing acute pain

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

Multiple sclerosis drug could help individuals with reduced working memory

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

Hypertension drug may reduce heart failure risk in people recovering from heart attack

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

Tirzepatide improves heart health and function in obese HFpEF patients

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News